Cervical Cancer - Prevention & Screening Tài liệu tham khảo

Cập nhật: 11 November 2024
  1. Benedet JL, Pecorelli S. Staging classification and clinical practice guidelines of gynaecological cancers by the FIGO Committee on Gynecologic Oncology. Elsevier. 2000 Sep. http://www.ginecologia.unipd.it/Assistenza-Documenti/Unita'%20operative/Ginecologia%20Oncologica/staging_booklet.pdf.
  2. Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting. University of Zimbabwe/JHPIEGO Cervical Cancer Project. Lancet. 1999 Mar;353(9156):869-873. PMID: 10093978
  3. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010 May;59(20):626-629. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 20508593
  4. Centers for Disease Control and Prevention (CDC). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007;56:1-24. http://www.cdc.gov. PMID: 17380109
  5. Chan PK, Ho WC, Wong MC, et al. Epidemiologic risk profile of infection with different groups of human papillomaviruses. J Med Virol. 2009 Sep;81(9):1635-1644. doi: 10.1002/jmv.21575. PMID: 19623668
  6. Domingo EJ, Dy Echo AV. Epidemiology, prevention and treatment of cervical cancer in the Philippines. J Gynecol Oncol. 2009 Mar;20(1):11-16. doi: 10.3802/jgo.2009.20.1.11. PMID: 19471671
  7. Dawar M, Deeks S, Dobson S. Human papillomavirus vaccines launch a new era in cervical cancer prevention. Can Med Assoc J. 2007 Aug;177(5):456-461. doi: 0.1503/cmaj.070771. PMID: 17724324
  8. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006 Aug;24:5937-5949. PMID: 16828940
  9. Collins Y, Einstein MH, Gostout BS, et al. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. Gynecol Oncol. 2006 Sep;102(3):552-562. PMID: 16979432
  10. Harper DM, Franco EL, Wheeler C, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus type 16 and 18: follow-up from a randomised control trial. Lancet. 2006 Apr;367(9518):1274-1255. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 16631880
  11. Hymel PA. Decreasing risk: impact of HPV vaccination on outcomes. Am J Manag Care. 2006 Dec;12(17 Suppl):S473-S483. PMID: 17203991
  12. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus type 16 and 18 in young women: a randomized controlled trial. Lancet. 2004;364(9447):1757-1765. http://www.ncbi.nlm.nih.gov/. PMID: 15541448
  13. Moyer VA; US Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012 Jun;156(12):880-891. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 22711081
  14. Muñoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety immunogenicity and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009 Jun;373(9679):1949-1957. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 19493565
  15. Jeronimo J, Morales O, Horna J, et al. Visual inspection with acetic acid for cervical cancer screening outside of low-resource settings. Rev Panam Salud Publica. 2005 Jan;17(1):1-5. http://www.ncbi.nlm.nih.gov/pubmed/?term=15720875. PMID: 15720875
  16. Obwegerser JH, Brack S. Does liquid-based technology really improve detection of cervical neoplasia? A prospective, randomized trial comparing the ThinPrep Pap test with the conventional Pap test, including follow-up of HSIL cases. Acta Cytol. 2001;45(5):709-714. http://www.ncbi.nlm.nih.gov/pubmed/?term=11575648. PMID: 11575648
  17. National Advisory Committee on Immunization (NACI), Public Health Agency of Canada. Update on human papillomavirus (HPV) vaccines. Canada Communicable Disease Report. 2012;38:1-62. http://www.phac-aspc.gc.ca. Accessed 31 Jan 2013
  18. Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009 Oct;5(10):696-704. http://www.ncbi.nlm.nih.gov/pubmed/?term=19855170. PMID: 19855170
  19. Ngelangel CA, Wang EH. Cancer and the Philippine Cancer Control Program. Jpn J Clin Oncol. 2002 Mar;32(Suppl 1):S52-S61. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 11959878
  20. Romanowski B, de Borba PC, Naud PS, et al; GSK Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine: analysis of a randomized placebo-controlled trial up 6.4 years [abstract]. Lancet. 2009 Dec;374(9706):1975-1985. doi: 10.1016/S0140-6736(09)61567-1. PMID: 19962185
  21. Sankaranarayanan R, Wesley R, Thara S, et al. Test characteristics of visual inspection with 4% acetic acid (VIA) and Lugol's iodine (VILI) in cervical cancer screening in Kerala, India. Int J Cancer. 2003 Sep;106(3):404-408. http://www.ncbi.nlm.nih.gov/pubmed/?term=12845681. PMID: 12845681
  22. Paavonen J, Naud P, Salmeron J, et al; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009 Jul;374(9686):301-314. doi: 10.1016/S0140-6736(09)61248-4. PMID: 19586656
  23. Saslow D, Castle PE, Cox JT, et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57(1):7-28. http://www.ncbi.nlm.nih.gov/pubmed/?term=17237032. PMID: 17237032
  24. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52(6):342-362. PMID: 12469763
  25. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147-172. http://www.ncbi.nlm.nih.gov/pubmed/?term=22422631. PMID: 22422631
  26. Wright TC Jr, Massad LS, Dunton CJ, for the 2006 American Society for Colposcopy and Cervical Pathology-sponsored consensus conference. 2006 Consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007 Oct;197(4):340-345. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 17904956
  27. Widdice LE, Kahn JA. Using the new HPV vaccines in clinical practice. Cleve Clin J Med. 2006 Oct;73(10):929-935. http://www.ncbi.nlm.nih.gov/pubmed/?term=17044318. PMID: 17044318
  28. MedWormhttp://www.medworm.com/rss/index.php/OBGYN/29/http://www.medworm.com/rss/medicalfeeds/specialities/OBGYN.xml
  29. MedWormhttp://www.medworm.com/rss/index.php/Cancer-%26-Oncology/6/http://www.medworm.com/rss/medicalfeeds/specialities/Cancer-Oncology.xml
  30. Advisory Committee on Immunization Practices (ACIP). ACIP provisional recommendations for HPV vaccine. Centers for Disease Control and Prevention (CDC). http://www.cdc.gov/vaccines. 01 Dec 2009.
  31. Centre for Health Protection, Scientific Committee on Preventable Diseases, Scientific Committee on AIDS and Sexually Transmitted Infections. Recommendation on the use of human papillomavirus (HPV) vaccine. http://www.chp.gov.hk. Feb 2008. Accessed 23 Nov 2010.
  32. Hong Kong College of Obstetricians and Gynaecologists (HKCOG). HKCOG guidelines: guidelines on the management of abnormal cervical cytology. Revised Nov 2008; Number 3. HKCOG. http://www.hkcog.org.hk. 2008. Accessed 02 Mar 2010.
  33. American Cancer Society. Cervical cancer: prevention and early detection. American Cancer Society. http://www.cancer.org. 2012.
  34. Ho TH, Chew SH, Ilancheran A, et al. Cervical Screen Singapore. Management guidelines for abnormal Pap smear & preinvasive disease of the cervix. Health Promotion Board. http://www.hpb.gov.sg. Accessed 02 Mar 2010.
  35. Ministry of Health Singapore. Cancer screening. MOH (Singapore). http://www.moh.gov.sg. Jan 2010. Accessed 09 Aug 2010.
  36. Ministry of Health Malaysia, Academy of Medicine Malaysia. Clinical practice guidelines: management of cervical cancer. Ministry of Health Malaysia. http://www.moh.gov.my. Apr 2003. Accessed 09 Aug 2010.
  37. Roteli-Martins C, Naud P, Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 ASO4-adjuvanted vaccine: follow-up to 8.4 years. Paper presented at 28th annual meeting of the European Society for Paediatric Infectious Diseases. 4-8 May 2010.
  38. Paavonen J, Naud P, Salmeron J, et al. P-689: End-of-study results of PATRICIA: a phase III efficacy study of HPV-16/18 ASO4-adjuvanted vaccine in young women. Paper presented at: 26th International Papillomavirus Conference & Clinical and Public Health Workshops. 2-8 Jul 2010; Quebec, Canada.
  39. Joseph GF. New ACOG cervical cancer screening recommendations. ACOG. http://www.acog.org. Nov 2009. Accessed 02 Mar 2010.
  40. Domingo EJ, Germar MJV. Cervical cancer. In: Society of Gynecologic Oncologists of the Philippines (Foundation), Inc. Clinical Practice Guidelines. 6th ed. Makati City, Philippines: OVT-Graphic Line, Inc; 2012:1-14.
  41. Massad LS, Einstein MH, Huh WK, et al; 2012 ASCCP Consensus Guidelines Conference. 2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013 Apr;17(5)(Suppl 1):S1-S27. doi: 10.1097/LGT.0b013e318287d329. PMID: 23519301
  42. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014 Aug;63(RR-05):1-30. http://www.cdc.gov/mmwr. Accessed 16 Sep 2014. PMID: 25167164
  43. Chatterjee A. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Rev Vaccines. 2014 Nov;13(11):1279-1290. doi: 10.1586/14760584.2014.963561. PMID: 25256262
  44. Himpunan Onkologi Ginekologi Indonesia (HOGI). Pedoman Pelayanan Medik Kanker Ginekologi. Edisi 2. Jakarta: Badan Penerbit FKUI; 2011.
  45. Markowitz L. 2-dose human papillomavirus (HPV) vaccination schedules. Centers for Disease Control and Prevention. http://www.cdc.gov/vaccines/acip. 25 Jun 2014.
  46. Public Health England, Department of Health, and NHS England. HPV vaccination programme: change from 3 to 2 doses. Joint letter on HPV vaccine schedule change: 14 May 2014. GOV.UK. https://www.gov.uk. 14 May 2014.
  47. World Health Organization (WHO). Comprehensive cervical cancer control: a guide to essential practice. 2nd ed. Geneva: WHO; 2014. http://www.ncbi.nlm.nih.gov. Accessed 04 Feb 2015:1-378.
  48. Petrosky E, Bocchini JA Jr, Hariri S, et al; Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):300-304. http://www.cdc.gov/mmwr. Accessed 10 Mar 2016. PMID: 25811679
  49. Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV vaccine. Centers for Disease Control and Prevention (CDC). http://www.cdc.gov. Jul 2015. Accessed 10 Mar 2016.
  50. Denny L, Quinn M. FIGO cancer report 2015. Int J Gynaecol Obstet. 2015 Oct;131(Suppl 2):S75. doi: 10.1016/j.ijgo.2015.06.024. Accessed 08 Dec 2016. PMID: 26433677
  51. American College of Obstetricians and Gynecologists. Practice bulletin no. 157: cervical cancer screening and prevention. Obstet Gynecol. 2016 Jan;127(1):e1-e20. doi: 10.1097/AOG.0000000000001263. PMID: 26695583
  52. Nayar R, Wilbur DC. The Pap test and Bethesda 2014. Acta Cytol. 2015;59(2):121-132. doi: 10.1159/000381842. Accessed 29 Nov 2016. PMID: 25997404
  53. Kim DK, Riley LE, Harriman KH, et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017 Feb 10;66(5):136-138. doi: 10.15585/mmwr.mm6605e2. Accessed 17 Mar 2017. PMID: 28182599
  54. Hong Kong College of Obstetricians and Gynaecologists (HKCOG). HKCOG guidelines: guidelines for cervical cancer prevention and screening. Revised Nov 2016; Number 4. HKCOG. http://www.hkcog.org.hk. Nov 2016. Accessed 11 Apr 2017.
  55. Philippine Cancer Society. Primary prevention of cancer. Philippine Cancer Society. http://www.philcancer.org.ph. 2011. Accessed 11 Apr 2017.
  56. Advisory Committee on Immunization Practices (ACIP). Recommended child and adolescent immunization schedule for ages 18 years or younger. Centers for Disease Control and Prevention (CDC). https://www.cdc.gov/vaccines/acip. 2020. Accessed 21 Dec 2020.
  57. American College of Obstetricians and Gynecologists’ Committee on Adolescent Health Care and Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group. Human papillomavirus vaccination: ACOG Committee Opinion, number 809. Obstet Gynecol. 2020 Aug;136(2):e15-e21. doi: 10.1097/AOG.0000000000004000. PMID: 32732766
  58. Cervical Screen Singapore Advisory Committee. Management guidelines for cervical screening and preinvasive disease of the cervix. SCCPS. https://www.sccps.org. Feb 2019. Accessed 21 Dec 2020.
  59. Feldman S, Goodman A, Peipert JF. Screening for cervical cancer in resource-rich settings. UpToDate. https://www.uptodate.com. Jun 2022. Accessed 21 Dec 2020.
  60. Teoh D, Musa F, Salani R, et al. Diagnosis and management of adenocarcinoma in situ: a Society of Gynecologic Oncology evidence-based review and recommendations. Obstet Gynecol. 2020 Apr;135(4):869-878. doi: 10.1097/AOG.0000000000003761. Accessed 21 Dec 2020. PMID: 32168211
  61. Advisory Committee on Immunization Practices (ACIP). Recommended adult immunization schedule for ages 19 years or older. Centers for Disease Control and Prevention (CDC). https://www.cdc.gov/vaccines/acip. 2020.
  62. Einstein MH. Human papillomavirus testing of the cervix: management of abnormal results. UpToDate. https://www.uptodate.com. 17 Jun 2019.
  63. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020 Sep;70(5):321-346. doi: 10.3322/caac.21628. PMID: 32729638
  64. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019 Aug;68(32):698–702. doi: 10.15585/mmwr.mm6832a3. PMID: 31415491
  65. PDQ® Screening and Prevention Editorial Board. PDQ Cervical cancer prevention. Bethesda, MD: National Cancer Institute. Updated 21 Aug 2020. https://www.cancer.gov. PMID: 26389433
  66. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020 Apr;24(2):102-131. doi: 10.1097/LGT.0000000000000525. Accessed 21 Dec 2020. PMID: 32243307
  67. American College of Obstetricians and Gynecologists. Updated cervical cancer screening guidelines. American College of Obstetricians and Gynecologists. https://www.acog.org/. Apr 2021. Accessed 09 Feb 2022.
  68. Cancer Expert Working Group on Cancer Prevention and Screening (CEWG). Recommendations on prevention and screening for cervical cancer for health professionals. Centre for Health Protection, The Government of Hong Kong Special Administrative Region, Department of Health. https://www.chp.gov.hk/. 2021. Accessed 09 Feb 2022.
  69. Ministry of Health Malaysia, Academy of Medicine. Clinical practice guidelines: management of cervical cancer. Ministry of Health Malaysia. http://www.moh.gov.my. 2017. Accessed 9 Feb 2022.
  70. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): cervical cancer. Version 1.2022. NCCN. https://www.nccn.org/. Oct 2021. Accessed 9 Feb 2022.
  71. Non-Communicable Disease Section (NCD), Disease Control Division, Ministry of Health Malaysia. Early detection of common cancers and referral pathways: module for health care providers. Ministry of Health Malaysia. http://www.moh.gov.my. 2017. Accessed 9 Feb 2022.
  72. US Preventive Services Task Force. Screening for cervical cancer. US Preventive Services Task Force recommendation statement. JAMA. 2018 Aug;320(7):674-686. doi: 10.1001/jama.2018.10897. Accessed 9 Feb 2022. PMID: 30140884
  73. World Health Organization (WHO). WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2nd ed. Geneva: WHO; 2021.
  74. Crum CP, Huh WK, Einstein MH. Cervical cancer screening: the cytology and human papillomavirus report. UpToDate. https://www.uptodate.com/. Jun 2021. Accessed 03 Aug 2022.
  75. Goodman A, Huh WK, Einstein MH. Cervical cancer screening: Management of results. UpToDate. https://www.uptodate.com/. Mar 2022.
  76. Centers for Disease Control and Prevention (CDC). HPV vaccination recommendations. CDC. https://www.cdc.gov/. 16 Nov 2021.
  77. Frumovitz F. Invasive cervical cancer: epidemiology, risk factors, clinical manifestations, and diagnosis. UpToDate. https://www.uptodate.com. 29 Mar 2023. Accessed 13 Apr 2023.
  78. Indonesian Society of Gynecologic Oncology (INASGO) 2023. Skrining kanker serviks dan tindak lanjut temuan abnormal. Himpunan Onkologi Ginekologi Indonesia (HOGI). Perkumpulan Obstetri dan Ginekologi Indonesia (POGI). Jakarta. http://inasgo.org/guideline.asp. Jan 2023. Accessed 13 Apr 2023.
  79. Lim TSC, Ismail-Pratt I, Goh LH. Cervical cancer screening and vaccination: understanding the latest guidelines. Singapore Med J. 2022 Mar;63(3):125-129. doi: 10.11622/smedj.2022045. Accessed 13 Apr 2023. PMID: 35509250
  80. Meites E, Gee J, Unger E, et al. Human papillomavirus. CDC. https://www.cdc.gov/. Aug 2021.
  81. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): cervical cancer. Version 1.2023. NCCN. https://www.nccn.org/. 06 Jan 2023.
  82. Tjokroprawiro BA, Yuliati I, Nuranna L, et al. Cervical cancer screening and prevention among female gynecologic oncologists in Indonesia. Bali Med J. 2023;12(1):1158-1162. doi: 10.15562/bmj.v12i1.3980.
  83. Apgar BS, Kaufman AJ, Bettcher C, et al. Gynecologic procedures: colposcopy, treatment for cervical intraepithelial neoplasia, and endometrial assessment. Am Fam Physician. 2013 Jun 15;87(12):836-843. https://www.aafp.org/. PMID: 23939565
  84. American Cancer Society. Cervical cancer: risk factors for cervical cancer. American Cancer Society. http://www.cancer.org. Jan 2020.
  85. Periodic Health Examination Task Force 2021. Philippine guidelines on periodic health examination: screening for neoplastic diseases. Department of Health Philippines. https://doh.gov.ph. 2021.
  86. Philippine Society for Cervical Pathology and Colposcopy. The PSCPC clinical practice guidelines for the management of abnormal cervical cancer screening results. Department of Health Philippines. https://doh.gov.ph. 2023.
  87. Chittithaworn S, Charakorn C, Kongsawatvorakul C. Cervical cancer screening guidelines: an updated review. Thai J Obstet Gynaecol. 2021 Jul;29(4):186-190. https://doi.org/10.14456/tjog.2021.22.
  88. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): Cervical cancer. Version 3.2024. NCCN. https://www.nccn.org/. May 2024.
  89. National Cancer Centre Singapore (NCCS). Cancer screening. NCCS. https://www.nccs.com.sg. 10 Oct 2023.
  90. Primary Care Pages. Cancer screening. Primary Care Pages. https://www.primarycarepages.sg. 03 Jul 2024.
  91. Rayner M, Welp A, Stoler MH, et al. Cervical cancer screening recommendations: now and for the future. Healthcare (Basel). 2023 Aug;11(16):2273. doi: 10.3390/healthcare11162273. PMID: 37628471
  92. World Health Organization (WHO). Cervical cancer. WHO. https://www.who.int/. 05 Mar 2024.
  93. World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper (2022 update). WHO. https://www.who.int/. Dec 2022.
  94. The Hong Kong College of Obstetricians and Gynaecologists (HKCOG). Guidelines for cervical cancer prevention and screening. HKCOG. https://www.hkcog.org.hk/. Jan 2024.
  95. American College of Obstetrician and Gynecologists (ACOG). Updated cervical cancer screening guidelines. ACOG. https://www.acog.org/. Apr 2024.
  96. del Carmen MG. Cervical adenocarcinoma in situ. UpToDate. https://www.uptodate.com/. 05 Feb 2025.
  97. Feldman S, Crum CP. Cervical cancer screening tests: techniques for cervical cytology and human papillomavirus testing. UpToDate. https://www.uptodate.com/. 30 Oct 2024.
  98. Family Health Development Division, Ministry of Health Malaysia. Guidelines for cervical cancer screening in Malaysia 2023. Ministry of Health Malaysia. https://www.moh.gov.my/. 2023.
  99. Feldman S, Goodman A, Peipert JF. Screening for cervical cancer in resource-rich settings. UpToDate. https://www.uptodate.com/. 29 Jan 2025.
  100. Goodman A, Kuh WK, Einstein MH. Cervical cancer screening: Risk assessment, evaluation, and management after screening. UpToDate. https://www.uptodate.com/. 15 Dec 2023.
  101. Wright JD. Cervical intraepithelial neoplasia: management. UpToDate. https://www.uptodate.com/. 24 Feb 2025.
  102. Wright JD. Cervical intraepithelial neoplasia: choosing excision versus ablation, and prognosis and follow-after treatment. UpToDate. https://www.uptodate.com/. 10 Mar 2025.